Back to Search
Start Over
Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77.
- Source :
-
International journal of biological macromolecules [Int J Biol Macromol] 2024 Sep; Vol. 276 (Pt 1), pp. 133706. Date of Electronic Publication: 2024 Jul 07. - Publication Year :
- 2024
-
Abstract
- Main proteases (M <superscript>pro</superscript> s) are a class of conserved cysteine hydrolases among coronaviruses and play a crucial role in viral replication. Therefore, M <superscript>pro</superscript> s are ideal targets for the development of pan-coronavirus drugs. X77, previously developed against SARS-CoV M <superscript>pro</superscript> , was repurposed as a non-covalent tight binder inhibitor against SARS-CoV-2 M <superscript>pro</superscript> during COVID-19 pandemic. Many novel inhibitors with favorable efficacy have been discovered using X77 as a reference, suggesting that X77 could be a valuable scaffold for drug design. However, the broad-spectrum performance of X77 and underlying mechanism remain less understood. Here, we reported the crystal structures of M <superscript>pro</superscript> s from SARS-CoV-2, SARS-CoV, and MERS-CoV, and several M <superscript>pro</superscript> mutants from SARS-CoV-2 variants bound to X77. A detailed analysis of these structures revealed key structural determinants essential for interaction and elucidated the binding modes of X77 with different coronaviral M <superscript>pro</superscript> s. The potencies of X77 against these investigated M <superscript>pro</superscript> s were further evaluated through molecular dynamic simulation and binding free energy calculation. These data provide molecular insights into broad-spectrum inhibition against coronaviral M <superscript>pro</superscript> s by X77 and the similarities and differences of X77 when bound to various M <superscript>pro</superscript> s, which will promote X77-based design of novel antivirals with broad-spectrum efficacy against different coronaviruses and SARS-CoV-2 variants.<br />Competing Interests: Declaration of competing interest The authors declare that there is no conflicts of interests.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Subjects :
- Crystallography, X-Ray
Antiviral Agents chemistry
Antiviral Agents pharmacology
Humans
Protein Binding
Protease Inhibitors chemistry
Protease Inhibitors pharmacology
COVID-19 virology
Severe acute respiratory syndrome-related coronavirus enzymology
Betacoronavirus enzymology
Betacoronavirus drug effects
Middle East Respiratory Syndrome Coronavirus enzymology
Middle East Respiratory Syndrome Coronavirus drug effects
Cysteine Endopeptidases chemistry
Cysteine Endopeptidases metabolism
Viral Nonstructural Proteins chemistry
Viral Nonstructural Proteins antagonists & inhibitors
Viral Nonstructural Proteins metabolism
Binding Sites
Coronavirus Infections virology
Coronavirus Infections drug therapy
Pandemics
Pneumonia, Viral virology
Pneumonia, Viral drug therapy
SARS-CoV-2 enzymology
SARS-CoV-2 drug effects
Molecular Dynamics Simulation
Coronavirus 3C Proteases antagonists & inhibitors
Coronavirus 3C Proteases chemistry
Coronavirus 3C Proteases metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0003
- Volume :
- 276
- Issue :
- Pt 1
- Database :
- MEDLINE
- Journal :
- International journal of biological macromolecules
- Publication Type :
- Academic Journal
- Accession number :
- 38981557
- Full Text :
- https://doi.org/10.1016/j.ijbiomac.2024.133706